Differences more than skin deep

Unexplained skin lesions seen in primates receiving Galvus vildagliptin, a selective DPP-4 inhibitor for Type II diabetes, are probably what caused FDA to issue an approvable letter last week that requested a new study in patients with renal impairment. Merck & Co. Inc. ran such a study for its selective DPP-4 inhibitor, Januvia sitagliptin, which was approved in October. But

Read the full 608 word article

How to gain access

Continue reading with a
two-week free trial.